Full-Time

Senior Director, SEC Reporting & SOX

SEC Reporting & SOX

Eikon Therapeutics

Eikon Therapeutics

201-500 employees

Develops therapies with single-molecule tracking

Compensation Overview

$235k - $283.5k/yr

San Bruno, CA, USA

In Person

On-site in Millbrae, California; no remote work option stated.

Bachelor's, Master's, PhD

Category
Accounting (1)

Get referred to Eikon Therapeutics

See people who can refer or advise you

Requirements
  • Bachelor's degree with 15+ years of experience or a post-graduate degree in Finance and Accounting.
  • 12+ years of experience in public accounting and/or related industry experience.
  • 6+ years with a technical accounting focus; deep technical proficiency across various areas of US GAAP and ability to research independently.
  • Strong understanding of US GAAP, SEC regulations, SOX, and internal control frameworks.
  • Experience building and scaling teams, systems, and processes in high-growth, evolving environments.
  • Exceptional communication, influence, and negotiation skills, with the ability to partner effectively with executive leadership and external stakeholders.
Responsibilities
  • Lead the company’s SEC reporting strategy and execution, including preparation and review of Forms 10-K, 10-Q, 8-K, proxy statements and other required filings, ensuring accuracy, completeness, and timeliness.
  • Coordinate with internal teams such as Legal, FP&A, and Stock Administration to collect required data for disclosures.
  • Serve as a key point of contact for external auditors by providing support schedules, documentation, and responses during audits and reviews.
  • Prepare and review external reporting components tied to the close process, including cash flow statements, equity, and share based compensation.
  • Establish, implement, and continuously evolve a Sarbanes-Oxley (SOX) compliance framework, including risk assessment, control design, documentation, testing, remediation, and optimization as the company scales.
  • Develop and implement company-wide policies, practices, and governance structures related to financial reporting and internal controls, ensuring alignment with regulatory requirements and business needs.
  • Execute the company’s SOX compliance program and assist with conducting audits of select operational, information technology, and compliance processes in timely manner.
  • Act as a strategic partner to executive leadership, providing insight, guidance, and influence on financial reporting, compliance, and risk management matters.
  • Serve as a technical accounting expert – proactively evaluate complex transactions and provide technical accounting guidance and disclosure recommendations, ensuring compliance with US GAAP and SEC reporting requirements.
  • Anticipate regulatory, operational, and organizational factors that could influence reporting strategy and company positioning, and proactively recommend solutions.
  • Stay current on FASB and SEC pronouncements and interpret impact to the company in partnership with internal partners and external auditors and identify, research, and prepare technical memoranda for complex transactions.
  • Partner cross-functionally with Accounting, FP&A, Legal, IT, Internal Audit, and external auditors and advisors to ensure cohesive execution and shared ownership of outcomes.
  • Lead, mentor, and develop the SEC reporting and SOX organization, directly or through subordinate leaders, fostering high performance and continuous improvement.
  • Oversee external audit relationships and third-party advisors, ensuring effective coordination and high-quality deliverables.
  • Drive initiatives that solve company-wide, cross-functional challenges, balancing speed, accuracy, and long-term sustainability.
Desired Qualifications
  • Biotech or life sciences experience strongly preferred.
  • SAP S4/Hana and ActiveDisclosure experience preferred.
  • CPA, CIA or similar certification preferred.

Eikon Therapeutics discovers and develops new medicines by studying the behavior of biological systems. The company uses a proprietary single-molecule tracking (SMT) platform combined with artificial intelligence to visualize and measure protein motion in living cells in real-time. Unlike competitors that often rely on static snapshots of chemical processes, Eikon focuses on the dynamic aspects of biology to identify drug targets with high precision. Its goal is to leverage this large-scale molecular data to invent and commercialize therapies for patients with serious diseases.

Company Size

201-500

Company Stage

IPO

Headquarters

Hayward, California

Founded

2019

Get referred to Eikon Therapeutics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 13, 2026 10-Q shows $531.2 million cash and runway into second half 2027.
  • July 20, 2026 ESMO accepted seven abstracts, signaling breadth across NSCLC, melanoma, prostate, and solid tumors.
  • EIK1001 advanced through first interim TeLuRide-006 analysis; ASCO 2026 and ESMO 2026 data follow.

What critics are saying

  • Eikon burned $88.4 million in Q2 2026 and still carries a $1.1 billion deficit.
  • EIK1001, EIK1003, and EIK1005 remain clinically unproven; one bad readout crushes the IPO story.
  • August 3, 2026 lock-up expiration released 32.9 million shares; insider selling can pressure EIKN.

What makes Eikon Therapeutics unique

  • Eikon's single-molecule tracking platform directly measures protein motion in living cells.
  • August 2026 pipeline spans EIK1001, EIK1003, EIK1004, and EIK1005 across oncology mechanisms.
  • TeLuRide-006 became a registrational Phase 2/3 melanoma trial after August 11, 2026 dose selection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

401(k) Company Match

Medical (premiums covered by Eikon at 95%)

Dental Insurance

Vision Insurance

Mental Health Support

Unlimited Paid Time Off

Paid Holidays

Life Insurance

Enhanced Parental Leave

Daily subsidized lunch program

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

-5%

2 year growth

-2%
Associated Press
Aug 13th, 2026
Eikon Therapeutics reports Q2 2026 results with $531.2M cash, seven ESMO abstracts on oncology pipeline

Eikon Therapeutics reported second quarter 2026 financial results and clinical updates across its oncology pipeline. The company had $531.2 million in cash, cash equivalents and marketable securities as of 30 June 2026, expected to fund operations into the second half of 2027. Seven abstracts were accepted for presentation at the European Society for Medical Oncology Congress 2026, covering clinical candidates EIK1001, EIK1003, EIK1004 and EIK1005. The company progressed its TeLuRide-006 Phase 2/3 registrational trial of EIK1001 through a first interim analysis for first-line advanced melanoma treatment. Net loss attributable to common stockholders was $88.4 million for the second quarter of 2026, compared to $105.2 million in the prior-year period. Research and development expenses increased 9% to $75.5 million, whilst general and administrative expenses decreased 56% to $17.9 million.

Yahoo Finance
Jun 8th, 2026
Eikon Therapeutics appoints former P&G executive Ma. Fatima Francisco to board of directors

Eikon Therapeutics has appointed Ma. Fatima Francisco as an independent director to its board, effective 15 June 2026. Francisco will also serve on the board's Compensation Committee. Francisco most recently served as chief executive officer of Baby, Feminine and Family Care at Procter & Gamble, where she led one of the company's largest global business units during a career spanning over 35 years. She currently serves on the boards of HP Inc. and Nestlé, and previously served on Organon's board. Eikon is a late-stage clinical biopharmaceutical company focused on developing cancer treatments using its proprietary single molecule tracking system. The company combines traditional biology research with advanced engineering to develop novel therapies addressing unmet medical needs.

Business Insider
May 21st, 2026
Eikon Therapeutics announces availability of six abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology.

Eikon Therapeutics announces availability of six abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology. May. 21, 2026, 05:05 PM * Presentations to cover progress across Eikon's most advanced clinical-stage programs * Updated data will include those derived from trials of EIK1001, for the treatment of patients with non-small cell lung cancer ("NSCLC"), EIK1003, as a monotherapy or in combination in the treatment of patients with breast, ovarian, prostate, or pancreatic cancer, and EIK1005, which is designed to improve treatment of patients whose tumors demonstrate certain DNA replication abnormalities. MILLBRAE, Calif., May 21, 2026 (GLOBE NEWSWIRE) - Eikon Therapeutics, Inc. (Nasdaq: EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the publication of full-text abstracts from its lead programs to be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago beginning on 29 May 2026. The six accepted presentations highlight clinical progress across Eikon's pipeline, including the TLR7 and TLR8 dual-agonist EIK1001 trials in NSCLC and advanced melanoma, updated data for its highly selective PARP1 inhibitor EIK1003, and early development progress for the WRN inhibitor candidate EIK1005. "We look forward to presenting these data at the ASCO Annual Meeting, which reflect the breadth of our oncology pipeline and our focus on advancing novel therapeutic approaches across multiple mechanisms and treatment settings," said Roger M. Perlmutter, M.D., Ph.D., Chief Executive Officer and Board Chair of Eikon. "Our programs are evaluating both monotherapy and combination strategies in patients with advanced disease, with the goal of generating insights that can inform patient selection, optimize treatment approaches, and ultimately support future registration of these novel therapeutics." 2026 ASCO Abstract Titles and Presentation Details: Title: Efficacy, safety and cytokine profiling with addition of the toll-like receptor (TLR) 7/8 dual agonist EIK1001 to Standard of Care First-Line Therapy: the Phase 2 TeLuRide-005 trial in Stage 4 Non-Small Cell Lung Cancer Title: Adaptive Phase 2/3 Study of EIK1001, a TLR7/8 Dual Agonist, in Combination with Pembrolizumab, as First-Line Therapy in Participants with Advanced Melanoma (TeLuRide-006) Title: A Phase 2/3 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Participants with Stage 4 Non-Small Cell Lung Cancer (TeLuRide-008) Title: EIK1003, a PARP1-selective inhibitor, in combination with paclitaxel (PTX): Initial combination and updated monotherapy results from a Phase 1/2 study EIK1003-001 in advanced solid tumors Title: First-in-Human Study to Evaluate the Safety, Tolerability, and PK of EIK1005, a Novel WRN Inhibitor in Healthy Participants Title: Phase 1/2 Study of the novel Werner helicase inhibitor EIK1005 as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors, including MSI-H or dMMR Tumors About Eikon Therapeutics Eikon is a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing innovative medicines to address serious unmet medical needs. Eikon's initial focus is oncology, where it is advancing a pipeline of drug candidates targeting areas of high unmet need that could eventually become critical medicines for the treatment of various cancers. Eikon deploys its technology platform, including its proprietary single molecule tracking system, to develop internally-derived novel therapies, while also leveraging the deep expertise of its management team to in-license promising assets. Eikon's vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. For more information, visit www.eikontx.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. All statements in this press release that are not historical facts are hereby identified as forward-looking statements for this purpose. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will" and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the therapeutic potential of Eikon's product candidates; the timing for anticipated data readouts; expected milestones and business objectives for 2026 and beyond, including Eikon's anticipated presentations at the ASCO Annual Meeting; and other statements regarding Eikon's future operations, financial performance, financial position, prospects, objectives, strategies and other future events. These forward-looking statements are based upon management's current expectations and assumptions, and are subject to a number of risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others: our limited operating history; our significant net losses incurred since inception and the likelihood of incurring additional losses for the foreseeable future; our need for substantial additional funding; the early stage of development of many of our product candidates and the possibility that our product candidates may fail in development; our dependence on the success of our current product candidates; our ability to leverage our technology platform to enable more informed drug research and development; legal and regulatory risks; intellectual property-related risks; and those risks, uncertainties and other factors discussed under the caption "Risk Factors" and elsewhere in Eikon's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed with the Securities and Exchange Commission ("SEC") on May 11, 2026, and in other public filings with the SEC in the future. As a result, you should not place undue reliance on any forward-looking statements. The forward-looking statements made in this press release speak only as of the date of this press release, and Eikon undertakes no obligation to update such forward-looking statements, whether as a result of new information, future developments or otherwise, except as required by law. Investors Alfred "Freddie" Bowie, Ph.D., CFO [email protected] Markets Insider and Business Insider Editorial Teams were not involved in the creation of this post. Sponsored Financial Content Five-star memories in Punta Cana.Not all memories feel the same. At Grand Palladium Hotels & Resorts, yours include waking up to the Caribbean Sea, dining under the stars, and the privilege of having everything taken care ofPalladium Hotel Group | Sponsored

The News Courier
May 21st, 2026
Eikon Therapeutics announces availability of six abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology.

Eikon Therapeutics announces availability of six abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology. GlobeNewswire | Eikon Therapeutics, Inc. Today at 2:05pm PDT * Presentations to cover progress across Eikon's most advanced clinical-stage programs * Updated data will include those derived from trials of EIK1001, for the treatment of patients with non-small cell lung cancer ("NSCLC"), EIK1003, as a monotherapy or in combination in the treatment of patients with breast, ovarian, prostate, or pancreatic cancer, and EIK1005, which is designed to improve treatment of patients whose tumors demonstrate certain DNA replication abnormalities. MILLBRAE, Calif., May 21, 2026 (GLOBE NEWSWIRE) - Eikon Therapeutics, Inc. (Nasdaq: EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the publication of full-text abstracts from its lead programs to be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago beginning on 29 May 2026. The six accepted presentations highlight clinical progress across Eikon's pipeline, including the TLR7 and TLR8 dual-agonist EIK1001 trials in NSCLC and advanced melanoma, updated data for its highly selective PARP1 inhibitor EIK1003, and early development progress for the WRN inhibitor candidate EIK1005. "We look forward to presenting these data at the ASCO Annual Meeting, which reflect the breadth of our oncology pipeline and our focus on advancing novel therapeutic approaches across multiple mechanisms and treatment settings," said Roger M. Perlmutter, M.D., Ph.D., Chief Executive Officer and Board Chair of Eikon. "Our programs are evaluating both monotherapy and combination strategies in patients with advanced disease, with the goal of generating insights that can inform patient selection, optimize treatment approaches, and ultimately support future registration of these novel therapeutics." 2026 ASCO Abstract Titles and Presentation Details: Title: Efficacy, safety and cytokine profiling with addition of the toll-like receptor (TLR) 7/8 dual agonist EIK1001 to Standard of Care First-Line Therapy: the Phase 2 TeLuRide-005 trial in Stage 4 Non-Small Cell Lung Cancer Title: Adaptive Phase 2/3 Study of EIK1001, a TLR7/8 Dual Agonist, in Combination with Pembrolizumab, as First-Line Therapy in Participants with Advanced Melanoma (TeLuRide-006) Title: A Phase 2/3 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Participants with Stage 4 Non-Small Cell Lung Cancer (TeLuRide-008) Title: EIK1003, a PARP1-selective inhibitor, in combination with paclitaxel (PTX): Initial combination and updated monotherapy results from a Phase 1/2 study EIK1003-001 in advanced solid tumors Title: First-in-Human Study to Evaluate the Safety, Tolerability, and PK of EIK1005, a Novel WRN Inhibitor in Healthy Participants Title: Phase 1/2 Study of the novel Werner helicase inhibitor EIK1005 as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors, including MSI-H or dMMR Tumors About Eikon Therapeutics Eikon is a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing innovative medicines to address serious unmet medical needs. Eikon's initial focus is oncology, where it is advancing a pipeline of drug candidates targeting areas of high unmet need that could eventually become critical medicines for the treatment of various cancers. Eikon deploys its technology platform, including its proprietary single molecule tracking system, to develop internally-derived novel therapies, while also leveraging the deep expertise of its management team to in-license promising assets. Eikon's vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. For more information, visit www.eikontx.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. All statements in this press release that are not historical facts are hereby identified as forward-looking statements for this purpose. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will" and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the therapeutic potential of Eikon's product candidates; the timing for anticipated data readouts; expected milestones and business objectives for 2026 and beyond, including Eikon's anticipated presentations at the ASCO Annual Meeting; and other statements regarding Eikon's future operations, financial performance, financial position, prospects, objectives, strategies and other future events. These forward-looking statements are based upon management's current expectations and assumptions, and are subject to a number of risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others: our limited operating history; our significant net losses incurred since inception and the likelihood of incurring additional losses for the foreseeable future; our need for substantial additional funding; the early stage of development of many of our product candidates and the possibility that our product candidates may fail in development; our dependence on the success of our current product candidates; our ability to leverage our technology platform to enable more informed drug research and development; legal and regulatory risks; intellectual property-related risks; and those risks, uncertainties and other factors discussed under the caption "Risk Factors" and elsewhere in Eikon's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed with the Securities and Exchange Commission ("SEC") on May 11, 2026, and in other public filings with the SEC in the future. As a result, you should not place undue reliance on any forward-looking statements. The forward-looking statements made in this press release speak only as of the date of this press release, and Eikon undertakes no obligation to update such forward-looking statements, whether as a result of new information, future developments or otherwise, except as required by law. Investors Alfred "Freddie" Bowie, Ph.D., CFO [email protected] This is a paid placement. For further inquiries, please contact GlobeNewswire directly.

Gridley Herald
Mar 30th, 2026
Eikon Therapeutics raises $381M in upsized IPO to advance cancer drug pipeline

Eikon Therapeutics, a late-stage clinical biopharmaceutical company, reported fourth quarter and full year 2025 financial results. The company completed an upsized IPO in February 2026, raising $381 million in gross proceeds. Eikon is advancing multiple clinical programmes, including EIK1001 for non-small cell lung cancer, with comprehensive data expected in the second half of 2026. The company's PARP1 inhibitors EIK1003 and EIK1004 are in Phase 1/2 trials, whilst EIK1005, a WRN helicase inhibitor, has begun patient trials. As of 31 December 2025, Eikon held $336 million in cash and marketable securities. The company expects its cash, including IPO proceeds, will fund operations into the second half of 2027. Net loss for 2025 was $333.6 million, compared to $243.8 million in 2024.